Dr. Mell on Risk Stratification for Head and Neck Cancer

Loren K. Mell, MD
Published: Tuesday, Nov 07, 2017



Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

According to Mell, it is important to understand which patients are likely to benefit from more or less intensive therapies.

Researchers are undergoing efforts to make staging patients more mathematical, explains Mell. Staging is used to get a sense for how extensive the cancer is and which treatment option will be most beneficial.



Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses risk stratification for patients with head and neck cancer.

According to Mell, it is important to understand which patients are likely to benefit from more or less intensive therapies.

Researchers are undergoing efforts to make staging patients more mathematical, explains Mell. Staging is used to get a sense for how extensive the cancer is and which treatment option will be most beneficial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x